A share price of Viking Therapeutics Inc [VKTX] is currently trading at $70.59, down -0.63%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VKTX shares have gain 8.52% over the last week, with a monthly amount glided 100.65%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, March 2024, Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares. In a post published today on Yahoo Finance, Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 7,441,650 shares of its common stock at a price to the public of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 970,650 additional shares of common stock. The gross proceeds to Viking from this offering were approximately $632.5 million, before deducting underwriting discounts and commissions and offering expenses.
From an analyst’s perspective:
Viking Therapeutics Inc [NASDAQ: VKTX] stock has seen the most recent analyst activity on March 07, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $110. Previously, Oppenheimer reaffirmed its Outperform rating on February 28, 2024, and elevated its price target to $116. Maxim Group reiterated its Buy rating and increased its price target to $25 on March 28, 2023. Stifel initiated its recommendation with a Buy and recommended $22 as its price target on March 17, 2023. In a note dated May 25, 2021, Raymond James downgraded an Outperform rating on this stock and revised its target price from $27 to $12.
Viking Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $8.28 and $99.41. Currently, Wall Street analysts expect the stock to reach $18.67 within the next 12 months. Viking Therapeutics Inc [NASDAQ: VKTX] shares were valued at $70.59 at the most recent close of the market. An investor can expect a potential drop of -73.55% based on the average VKTX price forecast.
Analyzing the VKTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.27 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 68.83 points at the first support level, and at 67.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 73.35, and for the 2nd resistance point, it is at 76.11.
Viking Therapeutics Inc [VKTX] reported earnings per share of -$0.25 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.25/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.23 per share as compared to estimates of -$0.22 per share, a difference of -$0.01 representing a surprise of -4.50%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Viking Therapeutics Inc [NASDAQ:VKTX] is 19.19. Also, the Quick Ratio is 19.19, while the Cash Ratio stands at 2.9.
Transactions by insiders
Recent insider trading involved Lian Brian, President & CEO, that happened on Feb 09 ’24 when 45000.0 shares were sold. President & CEO, Lian Brian completed a deal on Feb 08 ’24 to sell 0.27 million shares. Meanwhile, Director Rouan Sarah Kathryn sold 25000.0 shares on Feb 08 ’24.
